Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7203604 | 1.00 | ALDH1A1 (0.42) | ALDH1A1BCHEACHELMNATAAR1 | |
| SCHEMBL4350566 | 1.00 | ALDH1A1 (0.42) | ALDH1A1BCHEACHELMNATAAR1 | |
| SCHEMBL17541938 | 1.00 | ALDH1A1 (0.42) | ALDH1A1BCHEACHELMNATAAR1 | |
| SCHEMBL7203599 | 1.00 | ALDH1A1 (0.42) | ALDH1A1BCHEACHELMNATAAR1 | |
| SCHEMBL17541937 | 1.00 | ALDH1A1 (0.42) | ALDH1A1BCHEACHELMNATAAR1 | |
| SCHEMBL7790188 | 1.00 | ALDH1A1 (0.42) | ALDH1A1BCHEACHELMNATAAR1 | |
| SCHEMBL8080146 | 0.82 | LMNA (0.44) | ALDH1A1BCHEACHELMNATAAR1 | |
| SCHEMBL5213078 | 0.80 | CHRNB2 (0.42) | ALDH1A1BCHELMNATSHRMAPK1 | |
| SCHEMBL6784103 | 0.80 | CHRNB2 (0.42) | ALDH1A1BCHELMNATSHRMAPK1 | |
| SCHEMBL172658 | 0.80 | CHRNB2 (0.42) | ALDH1A1BCHELMNATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138179-A1 | Use of cytidine derivatives for the treatment of leukaemia | Shire Canada Inc. (CA) | 2009-12-30 | — | — | EP | disclosed |
| US-6964968-B2 | Method for the treatment or prevention of viral infection using nucleoside analogues | SHIRE BIOCHEM, INC. (CA) | 2005-11-15 | — | — | US | disclosed |
| US-20050101571-A1 | Methods of treating cancer using a combination of drugs | JOLIVET JACQUES (CA) | 2005-05-12 | — | — | US | disclosed |
| US-20040192654-A1 | Methods of treating leukemia | BIOCHEM PHARMA INC. (CA) | 2004-09-30 | — | — | US | disclosed |
| EP-1214074-B1 | DIOXOLANE NUCLEOSIDE ANALOGS FOR THE TREATMENT OR PREVENTION OF VIRAL INFECTION | SHIRE BIOCHEM INC (CA) | 2004-06-16 | — | — | EP | disclosed |
| US-6747036-B2 | USE OF NUCLEOSIDE ANALOGUES (CYTOSINE OR 5-FLUOROCYTOSINE CONTAINING COMPOUND) USEFUL FOR ACUTE OR CHRONIC MYELOGENOUS LEUKEMIA | BIOCHEM PHARMA INC. (CA) | 2004-06-08 | — | — | US | disclosed |
| US-20040014757-A1 | Method for the treatment or prevention of viral infection using nucleoside analogues | BIOCHEM PHARMA INC. (CA) | 2004-01-22 | — | — | US | disclosed |
| US-6630480-B1 | Methods of treating leukemia | BIOCHEM PHARMA INC. (CA) | 2003-10-07 | — | — | US | disclosed |
| US-6583149-B1 | 2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-Dioxolane | BIOCHEM PHARMA INC. (CA) | 2003-06-24 | — | — | US | disclosed |
| US-20030060476-A1 | Method and compositions for the synthesis of dioxolane nucleosides with beta-configuration | BIOCHEM PHARMA INC. | 2003-03-27 | — | — | US | disclosed |
| US-20030027799-A1 | Methods of treating cancer using a combination of drugs | SHIRE BIOCHEM INC. (CA) | 2003-02-06 | — | — | US | disclosed |
| US-20020107225-A1 | Methods of treating leukemia | BIOCHEM PHARMA INC. (CA) | 2002-08-08 | — | — | US | disclosed |
| US-20020058670-A1 | Method and compositions for the synthesis of dioxolane nucleosides with beta-configuration | BIOCHEM PHARMA INC. | 2002-05-16 | — | — | US | disclosed |
| EP-0970074-B1 | METHOD AND COMPOSITIONS FOR THE SYNTHESIS OF DIOXOLANE NUCLEOSIDES WITH BETA-CONFIGURATION | SHIRE BIOCHEM INC (CA) | 2002-03-20 | — | — | EP | disclosed |
| US-6069250-A | STEREOSELECTIVE SYNTHESIS OF THE BETA (CIS) ISOMER BY GLYCOSYLATING THE BASE WITH A 2-PROTECTED HYDROXYL-4-HALO-1,3-DIOXOLANE AT A TEMPERATURE OF-10 DEGREES C.; KINETICS | BIOCHEM PHARMA INC. (CA) | 2000-05-30 | — | — | US | disclosed |
| US-5922867-A | GLYCOSYLATING THE NUCLEOSIDE BASE WITH AN CHEMICAL INTERMEDIATE BELOW A TEMPERATURE OF ABOUT-10.DEGREE. C. | BIOCHEM PHARMA INC. (CA) | 1999-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060476-A1 | Method and compositions for the synthesis of dioxolane nucleosides with beta-configuration | DPYD, DHPS, DAD1 | ALDH1A1 497/4885BCHE 825/4885ACHE 2374/4885 |
| US-20030027799-A1 | Methods of treating cancer using a combination of drugs | TYMP, DPYD, MTHFD1 | ALDH1A1 107/4885BCHE 1746/4885ACHE 4389/4885 |
| US-20040014757-A1 | Method for the treatment or prevention of viral infection using nucleoside analogues | TREH, HPRT1, TYMP | ALDH1A1 3710/4885BCHE 1203/4885ACHE 1580/4885 |
| US-20020107225-A1 | Methods of treating leukemia | MCL1, HCCS, BCL9 | ALDH1A1 108/4885BCHE 2602/4885ACHE 4109/4885 |
| US-20040192654-A1 | Methods of treating leukemia | MCL1, HCCS, BCL9 | ALDH1A1 103/4885BCHE 2446/4885ACHE 4095/4885 |
| US-20020058670-A1 | Method and compositions for the synthesis of dioxolane nucleosides with beta-configuration | DPYD, DHPS, DAD1 | ALDH1A1 497/4885BCHE 825/4885ACHE 2374/4885 |
| US-20050101571-A1 | Methods of treating cancer using a combination of drugs | TYMP, DPYD, NTPCR | ALDH1A1 231/4885BCHE 1522/4885ACHE 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.